THC LAB Announces Arrangement With RYAH to Launch the RYAH Smart-Inhaler in the Italian and Dutch Markets

MIRANDOLA, ITALY / ACCESSWIRE / December 18, 2020 / THC Lab SRL. (“THC Lab” or the “Company”), announced that it has entered into a research-and-distribution arrangement with New York based RYAH Medtech Inc.

The agreement’s aim is to launch the RYAH IoT dose-measuring Smart-Inhaler and data analytics platform in Italy and the Netherlands, where THC Lab has a vast network of compounding pharmacies, cannabis clinics & physicians, cannabis patients associations and pharmaceutical distributors. The agreement also entails joint participation in a number of controlled research and bioavailability testing projects for the advancement of studying of the effectiveness of plant-based medicines in patients with various medical conditions.

The agreement and RYAH EU market entry are expected to accelerate an adoption of natural, dry-herb administration in both Italy and Netherlands, the second and third biggest medical cannabis markets in the EU. Until now physicians tended to prescribe cannabis oil extracts due to lack of appropriate inhalation technology, dose control and data analytics.

“We are confident that together with RYAH we will be able to increase considerably the share of inhaled medical cannabis currently estimated at only 10% in Italy and around 20% in the Netherlands. Our aim is to reach out to hundreds of pharmacies and establish RYAH as the market standard for vaporizing” said Andrea Ferrari, Sales Manager of THC Lab. “We are extremely excited about this new partnership and see tremendous synergies with our other commercial as well as scientific activities in the medical cannabis sector “.

THC Lab will also support RYAH in further optimizing the device by providing patients an integrated, in-app feedback forum within structured observational studies based on medical cannabis strains available in Italy and the Netherlands.

“We are thrilled by this cooperation as this gives us also the opportunity to contribute to the success and development of RYAH by providing our scientific input and carrying out joint observational studies on our patients” said Dr. Annunziata Lombardi, CEO & Technical Director of THC Lab.

About THC LAB SRL:
THC Lab specializes in providing products & services to compounding pharmacies in Italy and other European countries in the specific field of medical cannabis. One of the biggest cannabis compounding pharmacies in Italy and a specialized laboratory for cannabinoids analysis belong to the THC Lab group. This provides THC Lab with practical experience and a hands-on approach in all cannabis related businesses.

About RYAH Medtech, Inc.
RYAH Medtech Inc. (‘RYAH’) is a connected device and big data and technology company focused on valuable predictive analysis in the global medical plant intake industry. Its robust artificial intelligence platform aggregates and correlates HIPAA-compliant patient data, which is intended to help doctors and patients personalize plant-based treatments to better predict treatment outcomes. The data collection is relevant for clinics, doctors, dispensaries and pharmaceutical companies and Licensed Processors (LPs) to monitor and manage plant strain effects on patients. With a strong IP portfolio, RYAH gathers deep and insightful data on the complete medical plant lifecycle, from seed to consumption.

For further information please contact:
www.thclab.it
andrea.ferrari@thclab.it

SOURCE: THC Lab SRL

View source version on accesswire.com:
https://www.accesswire.com/621482/THC-LAB-Announces-Arrangement-With-RYAH-to-Launch-the-RYAH-Smart-Inhaler-in-the-Italian-and-Dutch-Markets

error: Content is protected !!